Revolution Medicines wins EU panel backing for pancreatic cancer drug Rasonque
The European Medicines Agency's advisory committee recommended approval of Revolution Medicines' Rasonque for adults with metastatic pancreatic cancer that has progressed after at least one prior therapy.
2 sourcesCancer treatment breakthroughs
00